Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system, and a key neurotransmitter in prefrontal cortical function. Converging lines of evidence implicate prefrontal cortical dysfunction in the neurobiology of schizophrenia. Thus, aberrant glutamate neurotransmission may underlie schizophrenia and other complex disorders of behavior. Group II metabotropic receptors (mGluRs) are important modulators of glutamatergic and non-glutamatergic neurotransmission. Moreover, in an animal model, an agonist for group II mGluRs has been shown to reverse the behavioral, locomotor, and cognitive effects of the psychotomimetic drug phencyclidine. Accordingly, group II mGluRs constitute attractive targets for the pharmacotherapeutics and study of schizophrenia. Using immunocytochemistry and Western immunoblotting, we compared the localization and levels of group II mGluRs in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Consistent with previous reports, we found that immunolabeling of group II mGluRs is prominent in Brodmann's area 46. The majority of labeling was present on axon terminals distributed in a lamina-specific fashion. No apparent difference in the cellular localization or laminar distribution of immunoreactive group II mGluRs was noted between the two diagnostic groups. Similarly, the levels of receptor immunoreactivity determined by quantitative Western immunoblotting were comparable between schizophrenic patients and normal subjects. We conclude that while the function of group II mGluRs in Brodmann's area 46 of dorsolateral prefrontal cortex may be altered in patients with schizophrenia, this is not evident at the level of protein expression using an antibody against mGluR2 and mGluR3. Molecular Psychiatry (2002) 7, 157-164.
Introduction
Glutamate is a primary excitatory neurotransmitter in the mammalian central nervous system (CNS), and a putative transmitter of many clinically important pathways. 1 Quantitatively, glutamate is the most abundant amino acid transmitter in the CNS, [1] [2] [3] [4] and glutamate receptors are located on virtually all neurons of the CNS. 4 In Brodmann's area (BA) 46 of the dorsolateral prefrontal cortex (DLPFC), pyramidal neurons appear to be glutamatergic, forming efferent corticofugal projections to other cortical and subcortical regions of the brain. 1 Taken together with the putative involvement of BA 46 in the pathophysiology of schizophrenia, [5] [6] [7] [8] [9] [10] [11] the general role of glutamate in CNS function and the anatomy of glutamatergic neurons in BA 46 support a key role for glutamate dysfunction in DLPFC of schizophrenia.
Hypothetical models of glutamate dysfunction in schizophrenia include hypofunction 12, 13 and hyperfunction 14, 15 of glutamate neurotransmission. The model of glutamate hypofunction is based, in part, on the psychotomimetic properties of phencyclidine (PCP) and ketamine. These N-methyl-D-aspartate (NMDA) ionotropic glutamate receptor antagonists can induce positive and negative symptoms in healthy individuals, [16] [17] [18] and the exacerbation of psychosis in patients with schizophrenia. 19, 20 In addition, PCP and ketamine impair performance on prefrontal cortexdependent cognitive tasks, [21] [22] [23] by interacting with dopamine neurotransmission, 14, 22, 24 mirroring cogni-tive impairment in schizophrenia. Assuming that PCP and ketamine act postsynaptically, and the resulting behavioral dysfunction is a valid model of schizophrenia, the behavioral abnormalities produced by these drugs suggest reduced glutamate tone in the DLPFC of patients with schizophrenia. Paradoxically, recent studies have shown that psychotomimetic NMDA receptor antagonists increase glutamate efflux, perhaps via presynaptic autoreceptors, [25] [26] [27] thereby potentiating PFC-glutamate neurotransmission at postsynaptic non-NMDA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainate) receptors.
14 Importantly, antagonism of ionotropic AMPA/kainate receptors in PFC attenuates mnemonic and other behavioral effects of NMDA receptor antagonism.
14 While most studies of glutamate receptor mediated neurotransmission in schizophrenia have focused on ionotropic glutamate receptors, recently, G-protein coupled mGluRs have received increased attention. 28, 29 As modulators of synaptic neurotransmission, 15, 30, 31 mGluRs are functionally related to NMDA, AMPA, and kainate receptors. Also, mGluRs are involved in neuroplasticity, 30, 32, 33 are characterized by a diversity of receptor subtypes and heterogeneous localization, 30, 34 and constitute attractive targets for the pharmacotherapeutics of psychiatric disorders associated with increased or decreased glutamate neurotransmission. 34, 35 The mGluRs currently recognized are classified into three groups according to sequence homology, signal transduction mechanism, and agonist selectivity. 34, 36 Group II mGluRs consist of mGluR2 and mGluR3, which modulate synaptic transmission through inhibition of cyclic AMP or calcium ion channels. 37, 38 Group II mGluRs are typically presynaptic autoreceptors, 30, 34 but also serve as presynaptic heteroceptors. 34 Moreover, they provide neuroprotection against glutamate-induced excitotoxicity, 39, 40 and are prevalent in frontal cortex. 41 Finally, in an animal model, group II mGluRs have been shown to mediate, in part, the disruptive behavioral, locomotor, and cognitive effects of PCP, and the concomitant cortical glutamate efflux. 15, 30, 34 Based on current understanding of the functional and anatomical characteristics of group II mGluRs, we hypothesized that the levels and/or anatomical distribution of these receptors are altered in BA 46 of the DLPFC from patients with schizophrenia compared to normal subjects. To investigate this hypothesis, we used immunocytochemistry with light microscopy to identify the localization of group II mGluRs in BA 46 of DLPFC from schizophrenic patients and normal subjects. In addition, we performed Western immunoblotting with scanning densitometry to measure mGluR2/3 receptor immunoreactivity in BA 46 of DLPFC from schizophrenic patients and normal subjects, including those chosen for immunocytochemistry studies.
Materials and methods

Tissue collection
After gaining the consent of a donor's legal next of kin, human DLPFC was obtained at autopsy through the Medical Examiners' Office of the District of Columbia (Washington DC, USA). All tissue was obtained and processed in accordance with a research protocol reviewed and approved by the Institutional Review Board of the National Institute of Mental Health, in conformance with the standards and guidelines of the National Institutes of Health. Tissue specimens were collected from 20 patients with a diagnosis of schizophrenia and 20 subjects with no clinical history of psychiatric illness or neuroleptic exposure (normal subjects). Patient diagnoses were confirmed after an independent review of medical records by two board certified psychiatrists according to DSM-IV criteria. 42 A board certified neuropathologist conducted an examination of each case in order to exclude any subject with significant neuropathological abnormalities. Microscopic examination of brain tissue sections taken from multiple cerebral areas and stained with Bielschowsky's silver stain was performed to exclude the presence of pathology associated with Alzheimer's disease. Toxicology screens conducted on blood or brain samples showed no evidence of alcohol or drug abuse by any of the subjects studied.
Wherever possible, normal subjects were matched for gender, age at death, postmortem interval (PMI; the time between death and freezing of brain tissue), and pH of tissue to subjects who had schizophrenia (Table  1) . Where death was not witnessed (normal subjects: ID 7, 8; schizophrenic patients: ID 4, 6; Table 1 ), PMI was taken as the interval half way between the last sighting of a subject while still alive and being found dead (less than 12 h), to the time of tissue freezing. For schizophrenic patients, duration of illness (DOI; the time from first hospital admission to death), and final and average daily antipsychotic drug doses (calculated as chlorpromazine equivalents) were determined from the medical records (Table 1) .
Following autopsy, the cerebral hemispheres of each brain were blocked coronally and flash frozen using a mixture of dry ice and isopentane. Tissue blocks were stored at −80°C until required (freezer time, FT; Table  1 ). The selection of tissue blocks containing BA 46 of DLPFC was standardized between subjects. Blocks extended rostral to the genu of the corpus callosum and contained the middle frontal gyrus. For immunocytochemistry, 14-m tissue sections were cut at −20°C using a cryo-microtome (CM 3050, Leica Microsystems, Deerfield, IL, USA), and thaw-mounted onto chromealum/gelatin-coated glass slides and stored at −80°C until required.
Immunocytochemistry
Mounted tissue sections (two per subject) were removed from −80°C, briefly thawed at room temperature (RT), and fixed for 2 h at 4°C in 4% phosphatebuffered paraformaldehyde (pH 7.2). Sections were washed three times for 5 min in 0.02 M phosphate- buffered saline (PBS; pH 7.4), and incubated with 1% H 2 O 2 for 8 min at RT to reduce the activity of endogenous peroxidases. Sections were again washed, and incubated in humidified chambers with 10% normal goat serum in blocking solution (1% bovine serum albumin (BSA; Sigma, St Louis, MO, USA), 0.1% Triton X-100 (Sigma), and PBS) for 30 min at RT to block non-specific labeling. Serum was removed, and the sections were incubated overnight at 4°C in humidified chambers with affinity-purified rabbit polyclonal mGluR2/3 antibody (1:200 dilution; 1.5 g ml −1 ; raised against the carboxy terminus peptide of rat mGluR2 [NGREVVDSTTSSL] conjugated to BSA with glutaraldehyde; Chemicon International, Temecula, CA, USA) Molecular Psychiatry diluted in blocking solution. After washing, the sections were incubated for 1 h at RT with biotinylated goat anti-rabbit IgG secondary antibody (1:200 dilution; Vector Laboratories, Burlingame, CA, USA) diluted in blocking solution. Sections were washed again, and incubated with avidin-biotin/peroxidase complex solution (VECTASTAIN ABC Elite Kit; Vector Laboratories) for 1 h at RT. Sections were then washed, preincubated with 3,3Ј-diaminobenzidine (DAB; Sigma) for 30 min at RT, and finally reacted with DAB and 0.03% H 2 O 2 in PBS for 10 min at RT. After a final wash, sections were dehydrated, cleared in xylene, and coverslipped for light microscopic examination.
In addition to Western immunoblot studies of speci- ficity of antibody labeling, immunocytochemistry was performed on sections with the exclusion of the primary or secondary antibody. Tissue preparations were examined by light microscopy (Nikon, Eclipse E400). BA 46 was histologically characterized by applying cytoarchitectonic criteria to Nissl stained sections from each subject studied. 43 A few sections were counterstained with the modified Giemsa method previously described 44 in order to further facilitate characterization of laminar distribution.
Western immunoblotting with scanning densitometry
Tissue samples were removed from −80°C and immediately homogenized at 4°C in buffer (20 mM Tris-HCl (pH 7.4) containing 10% sucrose, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 20 mg ml −1 leupeptin, 10 mg ml
pepstatin A, 20 mg ml −1 chymostatin, 2 mg ml −1 aprotinin, and 10 mM benzamidine). Homogenates were centrifuged at 1000 g for 10 min at 4°C. The supernatant was re-centrifuged in buffer without sucrose, at 114 000 g for 20 min at 4°C. The resulting pellet was washed in the same buffer three times by resuspension, and centrifuged at 114 000 g for 20 min at 4°C. The pellet was resuspended in buffer and placed on ice. After determining the protein concentrations of isolated samples using Bio-Rad DC Protein Assay (BioRad Laboratories, Hercules, CA, USA), aliquots of samples (50 g of protein) were stored in Laemmli reducing sample buffer 45 at −80°C until required. Isolated samples (two per subject) were subjected to SDS-PAGE (7.5% polyacrylamide gels) and transferred by electroblotting to nitrocellulose membrane overnight. Blots were blocked for 2 h at RT in blocking buffer (5% non-fat dry milk, 0.1% Tween 20, 50 mM Tris-buffered saline (TBS; pH 7.5)), and incubated for 1 h at RT with the above described mGluR2/3 antibody (1:80 dilution, 1.25 g ml , goat anti-rabbit IgG) prepared in blocking buffer, and washed again. The immunoreactive proteins were detected using enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA) with exposure to Kodak BioMax film (Eastman Kodak Company, Rochester, NY, USA).
Specificity of primary and secondary antibodies was verified by performing Western immunoblot studies on samples under the following conditions: (1) an optimal (1:80 dilution) concentration of primary antibody preabsorbed for 2 h at 4°C with an excess of synthetic mGluR2 (6.25 g ml −1 ) peptide (Chemicon International); and (2) exclusion of the primary antibody.
Film-based images of Western immunoblots were scanned using a Hewlett-Packard Scanjet at 600 d.p.i. resolution. Quantitative analysis of mGluR2/3 immunopositive bands was performed on a Macintosh computer using the public domain NIH Image program (developed at the US National Institutes of Health and available on the Internet at http://rsb.info.nih.gov/nihimage/). Scanning densitometry was performed blind to diagnosis. Briefly, densitometric analysis was performed by plotting the intensity and area of each immunopositive band, and calculating the area under the curve.
To control for inter-blot variation, data from each immunoblot were standardized using immunopositive bands of two reference internal controls. Also, to confirm equal loading of total protein and thus control for intra-gel variation, Ponceau S Red staining of immunoblots was performed.
Statistical analysis
Due to the relatively robust size of the sample populations, together with a greater sensitivity (ie, greater statistical power) of normal distribution-based tests, parametric methods of analysis were considered appropriate for the present studies. Thus, an unpaired t-test was used to compare immunolabeling, age, PMI, FT, and pH between the schizophrenic and normal groups. Pearson Product-Moment correlation coefficients, derived using a staight-line fit, were used to assess the relationships between immunolabeling and age, PMI, FT, and pH, and where relevant, DOI, final recorded antipsychotic drug dose, and average daily antipsychotic drug dose. Analysis of covariance (ANCOVA) was performed to determine whether age at death, PMI, FT, or tissue pH were confounding variables in the comparison between immunoreactivity of schizophrenic and normal subjects.
Results
Immunocytochemistry
Light microscopy showed similar patterns of mGluR2/3 immunoreactivity in BA 46 for patients with schizophrenia and normal controls. Punctate immunostaining outlined unlabeled cell bodies throughout the thickness of cortex (Figure 1a) , with no labeling in the white matter. A band of highest-density immunolabeled puncta corresponded to cortical lamina III (Figure 1a) . Occasionally, thin, axon-like immunolabeled fibers were seen in superficial laminae. Immunolabeled puncta were observed surrounding predominantly pyramidal and occasionally non-pyramidal neuronal and glial profiles (Figure 1b-c) . A proportion of pyramidal neurons exhibited darkly stained puncta concentrated around the basal aspect of cell somata (Figure 1b) . Omission of the primary ( Figure  1d ) or secondary (Figure 1e ) antibody resulted in the absence of or minimal immunolabeling respectively.
Western immunoblotting with scanning densitometry
Western immunoblotting detected a major band of protein at ෂ 100 kDa in isolated protein from BA 46 of normal human DLPFC, consistent with the predicted mass Molecular Psychiatry of mGluR2 and mGluR3 (Figure 2a-c) . Preabsorbtion of an optimal concentration (1:80 dilution) of primary antibody with an excess of synthetic peptide ( Figure  2d -e) or omission of the primary antibody (Figure 2f ) resulted in an absence of immunoreactivity. There was no difference between the mean levels of mGluR2/3 immunoreactivity in tissue from schizophrenic and normal subject groups (t = 0.10, df = 38, P = 0.92; Table 1; Figure 3 ). Of the normal subject group, three individuals showed considerably higher immunoreactivity levels compared to other subjects (Table 1, Figure 3) . Importantly, although exclusion of the three outliers from an analysis of data resulted in lower mean immunoreactivity levels in tissue from normal subjects compared to schizophrenic patients (622 ± 48 and 788 ± 115 respectively; mean ± s.e.), this was not statistically significant (t = 1.25, df = 35, P = 0.22).
The mean age (t = 0.32, df = 38, P = 0.75), PMI (t = 1.7, df = 38, P = 0.10), FT (t = 0.33, df = 38, P = 0.74), and pH of tissue (t = 0.04, df = 38, P = 0.97), did not differ between the groups studied ( Table 1) . For the schizophrenic cohort, no relationship was found between immunoreactivity and age at death (r = 0.04, P = 0.85), PMI (r = −0.41, P = 0.07), and FT (−0.09, P = 0.69). There was a significant positive correlation between immunoreactivity in tissue of schizophrenic patients and tissue pH (r = 0.46, P = 0.04). For the control subjects, no relationship was found between immunoreactivity and PMI (r = −0.15, P = 0.53), FT (r = −0.31, P = 0.19), and tissue pH (r = 0.17, P = 0.47). Unlike schizophrenic patients, a significant negative correlation existed between immunoreactivity in tissue from control subjects and age at death (r = −0.55, P = 0.01). ANCOVA showed no effect of age at death, PMI, FT, or tissue pH on the comparison between immunoreactivity in tissue from schizophrenic and normal subjects (f = 0.20; df = 1, 34; P = 0.66). Finally, no relationship was demonstrated between immunoreactivity in tissue from schizophrenic subjects and DOI (r = 0.35, P = 0.14), final recorded antipsychotic drug dose (r = −0.32, P = 0.18), or average daily antipsychotic drug dose (r = −0.17, P = 0.47).
Discussion
Using an antibody selective for mGluR2/3, we examined the localization and levels of immunoreactivity of group II mGluRs in BA 46 of DLPFC from patients with schizophrenia and normal subjects. Importantly, studies to characterize the specificity of the antiserum used for both slide-based immunocytochemistry and Western immunoblotting are consistent with the recognition of group II mGluR proteins, as predicted from previous reports. 41, 46, 47 The immunocytochemical localization of group II mGluRs in BA 46 is consistent with the role of these receptors in the modulation of both excitatory and inhibitory neurotransmission, deemed critical for normal cortical function. mGluR2/3 immunolabeled terminals were closely associated with pyramidal and to a lesser extent non-pyramidal somata. Presynaptic receptor localization was supported by labeling of punctate elements at the periphery of cell bodies, including intense staining at the basal aspect of pyramidal somata. Taken together, our findings are consistent with significant evidence 30, 34, 41 for group II mGluRs acting as autoreceptors at glutamatergic synapses and heteroreceptors at inhibitory synapses in BA 46 of the DLPFC.
Although receptor localization studies demonstrate that group II mGluRs are anatomically positioned to underlie aberrant DLPFC function, this is not substantiated by quantitative studies of immunoreactivity. Thus, Western immunoblot data indicate that While the present research represents the first postmortem tissue study of mGluR2/3 protein expression in schizophrenia, previous studies have focused on possible changes to mGluR2 and mGluR3 mRNA expression in the disorder. Consistent with our findings, Richardson-Burns et al 28 found no change to mGluR2 and mGluR3 mRNA expression in the thalamus of patients with schizophrenia. Similarly, Oh-numa et al 29 found no change to mGluR3 mRNA expression in PFC of schizophrenic patients.
There are limitations to the present study, which should be considered when interpreting the data. First, while the functional and anatomical characteristics of group II mGluRs support a similar role for both mGluR2 and mGluR3 in glutamate neurotransmission and hence schizophrenia neurobiology, we cannot rule out subtype specific receptor changes due to receptor selective mechanisms. Accordingly, subtype receptor selective antibodies will be necessary to determine if each receptor is differentially altered. Similar to immunochemical studies, the future development of subtype receptor selective compounds for radioligand binding may prove useful to unmasking possible differences between mGluR2 and mGluR3 expression in schizophrenia. A second issue relates to the lack of anatomical resolution inherent with homogenized tissue studies. Using quantitative Western immunoblotting, laminae-and or cellular-specific differences in mGluR2/3 expression between the study groups would not be detectable. Finally, as all schizophrenic patients studied were treated with antipsychotic drugs prior to death, we cannot exclude an effect of drug treatment on mGluR2/3 expression. Drug treatment may primarily or secondarily affect the expression of mGluR2 and/or mGluR3 and mask possible changes associated with disease pathology. Interestingly, earlier animal studies indicate that levels of extracellular glutamate are not altered in PFC following chronic treatment with haloperidol. 48, 49 Moreover, behavioral studies do not support the involvement of group II mGluRs in the activity of conventional antipsychotic drugs. 50 In conclusion, it is clear that group II mGluRs are abundant in BA 46 of human DLPFC, and anatomically positioned to underlie cortical dysfunction. However, we were unable to find any appreciable change in the localization or level of mGluR2/3 immunoreactivity in BA 46 of schizophrenic patients. Alterations specific to mGluR2 or mGluR3, restricted to certain cortical laminae, and/or associated with particular cell populations may have been overlooked in the present study. The present shortfalls may, in part, be overcome with the development of subtype receptor selective antibodies for immunochemistry and pharmacological compounds for radioligand binding. Moreover, future studies using quantitative methods of immunohistochemistry may prove more useful for identifying ultrastructural changes in receptor levels and distribution. Finally, group II mGluRs continue to be of interest as targets for novel pharmacological agents for the treatment of schizophrenia. This is supported by the actions of recently developed mGluR2/3 selective agonists that show antispychotic activity, including activation of dopaminergic and serotonergic brain pathways previously associated with atypical antipsychotics, and with low propensity for extrapyramidal side effects. 51, 52 Molecular Psychiatry
